RxDoctor Payments Data

Kathleen Holleran, MD

Internal Medicine · Gibsonia, PANPI 1376508382

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 52 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$515
  • GSK$250
  • Pfizer$94
  • Astellas Pharma US Inc$65
  • Novo Nordisk$49
  • Dexcom, Inc.$45
  • plus $119 from 5 others

What the payments were for

  • Food & beverage$1,07294%
  • Education$656%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$41,323
Medicare patients
156
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$87,318
JardianceEmpagliflozin46$68,913
MounjaroTirzepatide57$60,613
EliquisApixaban40$38,040
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$27,273
TrulicityDulaglutide12$19,692
XareltoRivaroxaban15$17,581
MyrbetriqMirabegron28$16,811
SynthroidLevothyroxine Sodium84$4,273
Atorvastatin Calcium461$2,963
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,420
Levothyroxine Sodium313$2,258
Celecoxib30$1,909
Valsartan63$1,779
Metoprolol Succinate138$1,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$49$87,31870 claims
Lilly USA, LLCMounjaro, Trulicity$40$80,30569 claims
PfizerEliquis$94$38,04040 claims
GSKTrelegy Ellipta$250$27,27326 claims
Astellas Pharma US IncMyrbetriq$65$16,81128 claims
AbbVieSynthroid$515$4,27384 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Gibsonia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →